>
COMMANDS Global: GP Symbol: IBM FA
↑↓ Navigate Enter Open Esc Close ` Toggle

Summary

2.44 0.17 (7.49%) 09/04/2026
INmune Bio, Inc. (INMB)
Performance
Historical returns
1D
7.49%
1W
6.09%
1M
27.75%
3M
80.74%
6M
84.85%
1Y
27.08%
5Y
-91.24%
Snapshot
Key statistics
Close
2.44
Change
0.17
Change %
7.49%
Open
2.27
Day Range
2.22 – 2.45
Volume
316,440
Avg Vol (20d)
329,801
Rel Vol
0.96x
52W Range
1.09 - 2.50
vs 52W High
-2.36%
vs 52W Low
123.85%
Gap
-0.14
Market Cap
USD 64.87M
Beta
0.91
Price Chart
Advanced chartCompare
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Bull vs Bear
8 bullish · 0 bearish points
Bullish view
  • Holds 52.4% above its 200-day average.
  • Has recovered 117.9% off the 52-week low of $1.12.
  • Outperformed the S&P 500 by 89.0% over the last quarter (+93.7% against +4.7%).
  • Trades at just 3.1× the 2029 consensus EPS of $0.78.
  • Consensus has EPS compounding 146.2% a year to $1.92 by 2030, which grows the multiple down to 1.3×.
  • Beat consensus EPS in 7 of the last 8 quarters.
  • The Q2 '26 quarter beat on EPS by $0.16 (75.8% above consensus).
  • Consensus looks for 193,010.0% revenue growth in 2029 to $96.56M.
Bearish view

None of the valuation, growth and margin, earnings-execution, analyst or price-trend checks produced a bearish signal on current data.

Both sides are generated from reported financials, consensus estimates, analyst targets and the price series — not from opinion.
Notable Price Movement
Historical returns
Sep 4
2026
$2.44 7.49%Latest
INmune Bio rose 7.49% to $2.44, its biggest one-day gain in 4 weeks and a 1.6σ move against its 60-day volatility. This was largely stock-specific: the S&P 500 fell 0.39% while Healthcare peers (XLV) fell 1.04% that session, leaving about 7.8 points of the move unexplained by the market after adjusting for a 0.91 beta. Shares closed near the session high (96% of the day's range).
Aug 25
2026
$2.43 2.97%52W High
INmune Bio rose 2.97% to $2.43. This was largely stock-specific: the S&P 500 gained 0.32% while Healthcare peers (XLV) rose 0.34% that session, leaving about 2.6 points of the move unexplained by its sector. Shares opened with a 1.69% gap up, closed near the session high (89% of the day's range), set a 52-week closing high and marked a 3rd consecutive advance.
Aug 21
2026
$2.32 7.41%
INmune Bio rose 7.41% to $2.32, its biggest one-day gain in 2 weeks and a 1.6σ move against its 60-day volatility, on 1.6× average volume. This was largely stock-specific: the S&P 500 gained 0.41% while Healthcare peers (XLV) rose 1.29% that session, leaving about 6.1 points of the move unexplained by its sector. Shares opened with a 2.78% gap up and closed near the session high (81% of the day's range).
Aug 10
2026
$2.12 1.68%Earnings
INmune Bio rose 1.68% to $2.12. The move was broadly in line with its sector — the S&P 500 gained 0.01% while Healthcare peers (XLV) rose 1.84% the same session — so little of it was company-specific. Shares marked a 3rd consecutive advance. It came 2 sessions after the Q2 2026 print.
Aug 7
2026
$2.09 9.16%Earnings
INmune Bio rose 9.16% to $2.09, its biggest one-day gain in 1 month and a 1.8σ move against its 60-day volatility, on 1.9× average volume. This was largely stock-specific: the S&P 500 gained 0.57% while Healthcare peers (XLV) rose 0.58% that session, leaving about 8.6 points of the move unexplained by its sector. Shares opened with a 3.14% gap up and closed near the session high (89% of the day's range). This was the first session after Q2 2026 results: EPS of $-0.05 vs $-0.21 expected (a beat). Historically, after 1.8σ-or-larger up days, INmune Bio returned -2.06% on average over the following 5 sessions (41% positive, n=34).
Aug 6
2026
$1.91 0.53%Pre-Earnings
INmune Bio rose 0.53% to $1.91, though on light volume (0.4× the 20-day average). Shares opened with a 1.58% gap down and reversed through the session. The session traded into Q2 2026 results, released after the close that evening.
Computed from adjusted closes over the last 22 sessions; attribution vs SPY and XLV.
Price Performance
All periods
PeriodPeriod LowPeriod HighPerformance
1-Month1.84 +32.61%
on 08/06/26
Open 1.91
2.50 -2.36%
on 08/26/26
+0.53 (+27.75%)
since 08/06/26
3-Month1.20 +103.33%
on 06/09/26
Open 1.26
2.50 -2.36%
on 08/26/26
+1.18 (+93.65%)
since 06/05/26
6-Month1.09 +123.85%
on 03/31/26
Open 1.33
2.50 -2.36%
on 08/26/26
+1.11 (+83.46%)
since 03/06/26
YTD1.09 +123.85%
on 03/31/26
Open 1.54
2.50 -2.36%
on 08/26/26
+0.90 (+58.44%)
since 01/02/26
52-Week1.09 +123.85%
on 03/31/26
Open 1.92
2.50 -2.36%
on 08/26/26
+0.52 (+27.08%)
since 09/04/25
5-Year1.09 +123.85%
on 03/31/26
Open 20.03
30.37 -91.97%
on 09/07/21
-17.59 (-87.82%)
since 08/27/21
New Highs
Historical highs
5-Day
2×
0.00% from peak
1-Month
7×
-0.20% from peak
3-Month
22×
-0.20% from peak
6-Month
20×
-0.20% from peak
YTD
16×
-0.20% from peak
52-Week
12×
-0.20% from peak
2-Year
13×
-76.72% from peak
3-Year
17×
-82.58% from peak
5-Year
5×
-91.24% from peak
10-Year
n/a
not enough history
Financial SnapshotFY 2025
Full financials
Revenue
USD 50.00K
+257.1% YoY
Net Income
-USD 45.93M
+9.2% YoY
EPS
-1.86
-11.8% YoY
Gross Margin
100.0%
Operating Margin
-61,738.0%
Net Margin
-91,866.0%
EBITDA
-USD 45.85M
Free Cash Flow
-USD 23.62M
-47,248.0% margin
ROE
-195.3%
ROA
-142.0%
Debt / Equity
0.04x
net debt -USD 23.72M
Cash & Equiv.
USD 24.75M
News
All news
08/28 05:10 ET · seekingalpha.com
INmune Bio: CORDStrom In The Lead After Signs Of UK Regulatory Alignment
INmune Bio is significantly undervalued, with Ebstrocel for RDEB driving a compelling investment thesis amid regulatory alignment and a $67M market cap. Ebstrocel offers systemic itch reduction, differentiating it from competitors like KRYS's Vyjuvek, and is positioned for UK, EU, and US regulatory...
08/26 07:00 ET · globenewswire.com
INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings
Orphan Drug Designation application and pre-MAA Scientific Advice package submitted for Ebstrocel™ in RDEB Filings support a planned EU MAA in Q1 2027; orphan designation, if granted and maintained through approval, may provide regulatory incentives and 10 years of market exclusivity
08/07 08:04 ET · seekingalpha.com
INmune Bio Inc. (INMB) Q2 2026 Earnings Call Transcript
INmune Bio Inc. (INMB) Q2 2026 Earnings Call Transcript
08/06 23:04 ET · marketbeat.com
INmune Bio Q2 Earnings Call Highlights
INmune Bio NASDAQ: INMB outlined plans to file for conditional approval of its Ebstrocel cell therapy in the United Kingdom by the end of the third quarter or early in the fourth quarter of 2026, while reporting a narrower second-quarter net loss and cash runway into the second quarter of 2027.
07/31 07:00 ET · globenewswire.com
INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th
Management to host conference call and webcast at 4:30 pm ET on that day BOCA RATON, Fla, July 31, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced t that it will host a conference...
07/31 07:00 ET · globenewswire.com
INmune Bio Receives R&D Rebates of Approximately $4.6 Million
BOCA RATON, Fla. , July 31, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announced that on July 30, 2026, it received a research and development cash rebate from Australia of approximately...
07/30 07:00 ET · globenewswire.com
INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform
Global Experts in MSC Clinical Translation to Advise Ebstrocel™ Regulatory and Clinical Development and Guide Expansion of CORDStrom Product Opportunities
07/20 07:00 ET · globenewswire.com
INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform
Commercial-Ready Manufacturing Now Supports Planned Phase 3 Confirmation Trial, and US, EU and UK Regulatory Submissions for Future Commercial Supply. Company Expresses Support for MHRA Draft Rare Disease Therapies Regulatory Framework BOCA RATON, Fla, July 20, 2026 (GLOBE NEWSWIRE) -- INmune Bio...

Market News ×
Loading news…